BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older
The purpose of this study is to evaluate the safety and efficacy in the frontline treatment of ovarian cancer in participants 70 years of age and older in routine clinical practice in Belgium. Bevacizumab will be used in combination with carboplatin/paclitaxel followed by bevacizumab as maintenance in accordance with the Summary of Product Characteristics (SmPC).
Ovarian Cancer
DRUG: Bevacizumab|DRUG: Carboplatin|DRUG: Paclitaxel
Percentage of Participants with Adverse Events, Per routine clinical practice during bevacizumab treatment (up to 15 months)|Time to First Incidence of Adverse Events of Special Interest, Per routine clinical practice during bevacizumab treatment (up to 15 months)
Progression-Free Survival According to Response Evaluation Criteria in Solid Tumors (RECIST), Per routine clinical practice during bevacizumab treatment (up to 15 months) and at 6 and 12 months after end of bevacizumab (approximately 27 months overall)|Percentage of Participants with Complete or Partial Response According to RECIST, Per routine clinical practice during bevacizumab treatment (up to 15 months) and at 6 and 12 months after end of bevacizumab (approximately 27 months overall)|Overall Survival, Per routine clinical practice during bevacizumab treatment (up to 15 months) and at 6 and 12 months after end of bevacizumab (approximately 27 months overall)|Comprehensive Geriatric Assessment Subscale Scores, Baseline, end of chemotherapy (up to 18 weeks), and after 10 and 15 months of bevacizumab treatment or at disease progression (up to 15 months overall)|Dosage of Bevacizumab in Milligrams per Kilogram (mg/kg), Every 3 weeks according to SmPC for up to 15 months|Total Number of Bevacizumab Doses, Every 3 weeks according to SmPC for up to 15 months|Percentage of Participants by Chemotherapy Used in Combination with Bevacizumab, Every 3 weeks per routine clinical practice for up to 18 weeks
The purpose of this study is to evaluate the safety and efficacy in the frontline treatment of ovarian cancer in participants 70 years of age and older in routine clinical practice in Belgium. Bevacizumab will be used in combination with carboplatin/paclitaxel followed by bevacizumab as maintenance in accordance with the Summary of Product Characteristics (SmPC).